step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Pivotal Results for in Obesity A Placebo-Controlled Trial of Subcutaneous

The earlier we can stop it from spreading, the better the chances of long-term survival

Through the production of metabolites such as short-chain fatty acids, indole derivatives, and bile acidrelated molecules, and via receptor pathways including FFAR2/3, FXR, and TGR5, the microbiota modulates incretin secretion, tissue insulin sensitivity, immune tone, and the integrity of the intestinal epithelial barrier

Your provider chooses which one and at what dose based on your labs, health history, and goals

We'll review your health history, check insurance coverage, and build a treatment plan around your goals

MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate such robust efficacy in a Phase II study